105 Potential Immunological Triggers for Central Disorders of Hypersomnolence Table 2: Between-group immunological events comparisons Variable Narcolepsy type 1 (N = 194) Narcolepsy type 2 or idiopathic hypersomnia (N = 71) Odds ratio (95% CI) Effect size Corrected p-value Infections & influenza vaccinations N Percentage of N N Percentage of N Total immunological events prevalence 194 44.8% 71 50.7% 0.79 (0.46-1.36) 0.0520 0.5073 Distribution of immunological events 90 Flu: 14.4% EBV: 13.3% Other respiratory infection: 11.1% Other nonrespiratory infection: 12.2% H1N1 influenza vaccination: 36.7% Other years/ unspecified yearly: 12.2% 37 Flu: 5.4% EBV: 27.0% Other respiratory infection: 21.6% Other nonrespiratory infection: 21.6% H1N1 influenza vaccination: 5.4% Other years/ unspecified yearly: 18.9% - 0.3797 0.0193 Infections Total Infection prevalence 149 30.9% 44 63.6% 0.26 (0.13-0.52) 0.2827 0.0020 Flu infection prevalence 149 8.7% 44 4.5% 2.01 (0.44-9.26) 0.0655 0.6062# EBV infection prevalence 149 8.1% 44 22.7% 0.30 (0.12-0.75) 0.1937 0.0273 Other respiratory infection prevalence 149 6.7% 44 18.2% 0.32 (0.12-0.88) 0.1655 0.0707 4
RkJQdWJsaXNoZXIy MjY0ODMw